Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Ultra-sensitive ctDNA mutation tracking to identify molecular residual disease and predict relapse in patients with early breast cancer.

At a median follow-up of 76 months, ctDNA detection was associated with relapse (HR undefined, P<0.0001) and shorter OS (P<0.0001), with a median lead time of 12.5 months (range 1-60). MRD was identified in 10/10 patients who relapsed (median 18.5 PPM at first detection). None of 58 patients who remained ctDNA-undetected relapsed. Of patients undetected at the post-surgical landmark, 31/33 (94%) did not relapse. Forty percent of all detections were below 100 PPM.

ASCO Annual Meeting 2024